Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence

References

• International Agency for Research on Cancer. [webpage on the Internet]Cancer Today2016 Available from: http://gco.iarc.fr/todayAccessed December 12, 2017
   Google Scholar
• Cancer Genome Atlas NetworkComprehensive molecular portraits of human breast tumoursNature20124907418617023000897
   PubMed Web of Science ®Google Scholar
• PerouCMSørlieTEisenMBMolecular portraits of human breast tumoursNature2000406679774775210963602
   PubMed Web of Science ®Google Scholar
• SorlieTTibshiraniRParkerJRepeated observation of breast tumor subtypes in independent gene expression data setsProc Natl Acad Sci U S A2003100148418842312829800
   PubMed Web of Science ®Google Scholar
• BrentonJDCareyLAAhmedAACaldasCMolecular classification and molecular forecasting of breast cancer: ready for clinical application?J Clin Oncol200523297350736016145060
   PubMed Web of Science ®Google Scholar
• AdesFZardavasDBozovic-SpasojevicILuminal B breast cancer: molecular characterization, clinical management, and future perspectivesJ Clin Oncol201432252794280325049332
   PubMed Web of Science ®Google Scholar
• GoldhirschAWinerEPCoatesASPersonalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Ann Oncol20132492206222323917950
   PubMed Web of Science ®Google Scholar
• CardosoFCostaASenkusE3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)Ann Oncol2017281163328177437
   PubMed Web of Science ®Google Scholar
• MusgroveEASutherlandRLBiological determinants of endocrine resistance in breast cancerNat Rev Cancer20099963164319701242
   PubMed Web of Science ®Google Scholar
• MillerTWRexerBNGarrettJTArteagaCLMutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancerBreast Cancer Res201113622422114931
   PubMed Web of Science ®Google Scholar
• FrogneTJepsenJSLarsenSSFogCKBrockdorffBLLykkes-feldtAEAntiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growthEndocr Relat Cancer200512359961416172194
   PubMed Web of Science ®Google Scholar
• YamnikRLHolzMKmTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor α serine 167 phosphorylationFEBS Lett2010584112412819925796
   PubMed Web of Science ®Google Scholar
• HuiRFinneyGLCarrollJSLeeCSMusgroveEASutherlandRLConstitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cellsCancer Res200262236916692312460907
   PubMed Web of Science ®Google Scholar
• AlvesCLEliasDLyngMHigh CDK6 protects cells from fulvestrant-mediated apoptosis and is a predictor of resistance to fulvestrant in estrogen receptor-positive metastatic breast cancerClin Cancer Res201622225514552627252418
   PubMed Web of Science ®Google Scholar
• ThangavelCDeanJLErtelATherapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancerEndocr Relat Cancer201118333334521367843
   PubMed Web of Science ®Google Scholar
• JeselsohnRBuchwalterGde AngelisCBrownMSchiffRESR1 mutations: a mechanism for acquired endocrine resistance in breast cancerNat Rev Clin Oncol2015121057358326122181
   PubMed Web of Science ®Google Scholar
• WakelingAEDukesMBowlerJA potent specific pure antiestrogen with clinical potentialCancer Res19915115386738731855205
   PubMed Web of Science ®Google Scholar
• OsborneCKSchiffREstrogen-receptor biology: continuing progress and therapeutic implicationsJ Clin Oncol20052381616162215755967
   PubMed Web of Science ®Google Scholar
• JordanVCO’MalleyBWSelective estrogen-receptor modulators and antihormonal resistance in breast cancerJ Clin Oncol200725365815582417893378
   PubMed Web of Science ®Google Scholar
• OsborneCKWakelingANicholsonRIFulvestrant: an oestrogen receptor antagonist with a novel mechanism of actionBr J Cancer200490Suppl 1S2S615094757
   PubMed Web of Science ®Google Scholar
• KumarVGreenSStackGBerryMJinJRChambonPFunctional domains of the human estrogen receptorCell19875169419513690665
   PubMed Web of Science ®Google Scholar
• KatoSEndohHMasuhiroYActivation of the estrogen receptor through phosphorylation by mitogen-activated protein kinaseScience19952705241149114947491495
   PubMed Web of Science ®Google Scholar
• FawellSEWhiteRHoareSSydenhamMPageMParkerMGInhibition of estrogen receptor-DNA binding by the “pure” antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerizationProc Natl Acad Sci U S A19908717688368872395882
   PubMed Web of Science ®Google Scholar
• DauvoisSWhiteRParkerMGThe antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttlingJ Cell Sci1993106Pt 4137713888126115
   PubMed Web of Science ®Google Scholar
• WakelingAEUse of pure antioestrogens to elucidate the mode of action of oestrogensBiochem Pharmacol19954911154515497786294
   PubMed Web of Science ®Google Scholar
• MoralesLNevenPTimmermanDProspective assessment of the endometrium in postmenopausal breast cancer patients treated with fulvestrantBreast Cancer Res Treat20091171778119048370
   PubMed Web of Science ®Google Scholar
• PeekhausNTChangTHayesECDistinct effects of the antiestrogen Faslodex on the stability of estrogen receptors-α and -β in the breast cancer cell line MCF-7J Mol Endocrinol200432398799515171727
   PubMed Web of Science ®Google Scholar
• MishraAKAbrahamssonADabrosinCFulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβOncotarget2016735568765688827486755
   PubMedGoogle Scholar
• McClellandRAGeeJMFrancisABShort-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancerEur J Cancer199632A34134168814683
   PubMed Web of Science ®Google Scholar
• InoueAYoshidaNOmotoYDevelopment of cDNA microarray for expression profiling of estrogen-responsive genesJ Mol Endocrinol200229217519212370120
   PubMed Web of Science ®Google Scholar
• dos SantosEGDieudonneMNPecqueryRle MoalVGiudicelliYLacasaDRapid nongenomic E2 effects on p42/p44 MAPK, activator protein-1, and cAMP response element binding protein in rat white adipocytesEndocrinology2002143393094011861515
   PubMed Web of Science ®Google Scholar
• HuXFVeroniMde LuiseMCircumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780Int J Cancer19935558738768244585
   PubMed Web of Science ®Google Scholar
• LykkesfeldtAEMadsenMWBriandPAltered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1Cancer Res1994546158715958137264
   PubMed Web of Science ®Google Scholar
• de CupisANoonanDPiraniPFerreraAClericoLFavoniREComparison between novel steroid-like and conventional nonste-roidal antioestrogens in inhibiting oestradiol- and IGF-I-induced proliferation of human breast cancer-derived cellsBr J Pharmacol19951165239124008581274
   PubMed Web of Science ®Google Scholar
• LykkesfeldtAELarsenSSBriandPHuman breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatmentInt J Cancer19956145295347759159
   PubMed Web of Science ®Google Scholar
• OsborneCKCoronado-HeinsohnEBHilsenbeckSGComparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancerJ Natl Cancer Inst199587107467507563152
   PubMed Web of Science ®Google Scholar
• DowsettMNicholsonRIPietrasRJBiological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistanceBreast Cancer Res Treat200593Suppl 1S11S1816247595
   PubMedGoogle Scholar
• DeFriendDJHowellANicholsonRIInvestigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancerCancer Res19945424084148275477
   PubMed Web of Science ®Google Scholar
• RobertsonJFNicholsonRIBundredNJComparison of the short-term biological effects of 7α-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17β-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancerCancer Res200161186739674611559545
   PubMed Web of Science ®Google Scholar
• AgrawalARobertsonJFCheungKLBiological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsiesInt J Cancer2016138114615926178788
   PubMed Web of Science ®Google Scholar
• KuterIGeeJMHeggRDose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized phase II studyBreast Cancer Res Treat2012133123724622286314
   PubMed Web of Science ®Google Scholar
• DeeksEDFulvestrant: a review in advanced breast cancer not previously treated with endocrine therapyDrugs201878113113729270913
   PubMed Web of Science ®Google Scholar
• HowellADeFriendDRobertsonJBlameyRWaltonPResponse to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancerLancet1995345894129307799704
   PubMed Web of Science ®Google Scholar
• HowellADeFriendDJRobertsonJFPharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancerBr J Cancer19967423003088688341
   PubMed Web of Science ®Google Scholar
• RobertsonJFEriksteinBOsborneKCPharmacokinetic profile of intramuscular fulvestrant in advanced breast cancerClin Pharmacokinet200443852953815170367
   PubMed Web of Science ®Google Scholar
• RobertsonJFOdling-SmeeWHolcombeCKohlhardtSRHarrisonMPPharmacokinetics of a single dose of fulvestrant prolonged-release intramuscular injection in postmenopausal women awaiting surgery for primary breast cancerClin Ther20032551440145212867220
   PubMed Web of Science ®Google Scholar
• RobertsonJFHarrisonMPEquivalent single-dose pharmacokinetics of two different dosing methods of prolonged-release fulvestrant (‘Faslodex’) in postmenopausal women with advanced breast cancerCancer Chemother Pharmacol200352434634812879276
   PubMed Web of Science ®Google Scholar
• RobertsonJFFulvestrant (Faslodex): how to make a good drug betterOncologist200712777478417673609
   PubMed Web of Science ®Google Scholar
• OhnoSRaiYIwataHThree dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1)Ann Oncol201021122342234720494961
   PubMed Web of Science ®Google Scholar
• PritchardKIRolskiJPapaiZResults of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)Breast Cancer Res Treat2010123245346120632084
   PubMed Web of Science ®Google Scholar
• ChiaSGradisharWMauriacLDouble-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECTJ Clin Oncol200826101664167018316794
   PubMed Web of Science ®Google Scholar
• McCormackPSapunarFPharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancerClin Breast Cancer20088434735118757262
   PubMed Web of Science ®Google Scholar
• OakmanCMorettiESantarpiaLDi LeoAFulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancerFuture Oncol20117217318621345137
   PubMed Web of Science ®Google Scholar
• LeeCIGoodwinAWilckenNFulvestrant for hormone-sensitive metastatic breast cancerCochrane Database Syst Rev20171CD01109328043088
   PubMedGoogle Scholar
• IngleJNSumanVJRowlandKMFulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032J Clin Oncol20062471052105616505423
   PubMed Web of Science ®Google Scholar
• PereyLParidaensRHawleHClinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)Ann Oncol2007181646917030543
   PubMed Web of Science ®Google Scholar
• FrancoSPerezATan-ChiuEFrankelCVogelCLResponse to fulvestrant in heavily pretreated postmenopausal women: a single-center experienceBreast Cancer Res Treat200488210310815564793
   PubMed Web of Science ®Google Scholar
• StegerGGBartschRWenzelCFulvestrant (‘Faslodex’) in pre-treated patients with advanced breast cancer: a single-centre experienceEur J Cancer200541172655266116230005
   PubMed Web of Science ®Google Scholar
• HowellARobertsonJFAlbanoJQFulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatmentJ Clin Oncol200220163396340312177099
   PubMed Web of Science ®Google Scholar
• OsborneCKPippenJJonesSEDouble-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trialJ Clin Oncol200220163386339512177098
   PubMed Web of Science ®Google Scholar
• RobertsonJFOsborneCKHowellAFulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trialsCancer200398222923812872340
   PubMed Web of Science ®Google Scholar
• MauriacLPippenJEAlbanoJQGertlerSZOsborneCKFulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trialsEur J Cancer20033991228123312763210
   PubMed Web of Science ®Google Scholar
• HowellAPippenJElledgeRMFulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trialsCancer2005104223623915937908
   PubMed Web of Science ®Google Scholar
• HowellARobertsonJFAbramPComparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trialJ Clin Oncol20042291605161315117982
   PubMed Web of Science ®Google Scholar
• Di LeoAJerusalemGPetruzelkaLResults of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancerJ Clin Oncol201028304594460020855825
   PubMed Web of Science ®Google Scholar
• Di LeoAJerusalemGPetruzelkaLFinal overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trialJ Natl Cancer Inst20141061djt33724317176
   PubMedGoogle Scholar
• Di LeoAJerusalemGTorresRFirst-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: a post-hoc analysis of the CONFIRM studyBreast20183814414929324303
   PubMed Web of Science ®Google Scholar
• JeselsohnRBarryWTMigliaccioITransCONFIRM: identification of a genetic signature of response to fulvestrant in advanced hormone receptor-positive breast cancerClin Cancer Res201622235755576427185372
   PubMed Web of Science ®Google Scholar
• RobertsonJFLlombart-CussacARolskiJActivity of ful-vestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST studyJ Clin Oncol200927274530453519704066
   PubMed Web of Science ®Google Scholar
• RobertsonJFLindemannJPLlombart-CussacAFulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ studyBreast Cancer Res Treat2012136250351123065000
   PubMed Web of Science ®Google Scholar
• EllisMJLlombart-CussacAFeltlDFulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST studyJ Clin Oncol201533323781378726371134
   PubMed Web of Science ®Google Scholar
• RobertsonJFBondarenkoIMTrishkinaEFulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trialLancet2016388100632997300527908454
   PubMed Web of Science ®Google Scholar
• YoungOERenshawLMacaskillEJEffects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancerEur J Cancer200844339139918083023
   PubMed Web of Science ®Google Scholar
• MasciGGandiniCZuradelliMFulvestrant for advanced male breast cancer patients: a case seriesAnn Oncol201122498521447621
   PubMed Web of Science ®Google Scholar
• ZagouriFSergentanisTNChrysikosDDimopoulosMAPsaltopoulouTFulvestrant and male breast cancer: a pooled analysisBreast Cancer Res Treat2015149126927525519043
   PubMed Web of Science ®Google Scholar
• JelovacDMacedoLGoloubevaOGHandrattaVBrodieAMAdditive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer modelCancer Res200565125439544415958593
   PubMed Web of Science ®Google Scholar
• RobertsonJFDixonJMSibberingDMA randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancerBreast Cancer Res2013152R1823497452
   PubMed Web of Science ®Google Scholar
• BerghJJönssonPELidbrinkEKFACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancerJ Clin Oncol201230161919192522370325
   PubMed Web of Science ®Google Scholar
• MehtaRSBarlowWEAlbainKSCombination anastrozole and fulvestrant in metastatic breast cancerN Engl J Med2012367543544422853014
   PubMed Web of Science ®Google Scholar
• JohnstonSRKilburnLSEllisPFulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trialLancet Oncol2013141098999823902874
   PubMed Web of Science ®Google Scholar
• FribbensCO’LearyBKilburnLPlasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancerJ Clin Oncol201634252961296827269946
   PubMed Web of Science ®Google Scholar
• RobertsonJFStegerGGNevenPActivity of fulvestrant in HER2-overexpressing advanced breast cancerAnn Oncol20102161246125319875750
   PubMed Web of Science ®Google Scholar
• Sonne-HansenKNorrieICEmdalKBBreast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistanceBreast Cancer Res Treat2010121360161319697122
   PubMed Web of Science ®Google Scholar
• ChenQWengZLuYAn experimental analysis of the molecular effects of trastuzumab (Herceptin) and fulvestrant (Falsodex), as single agents or in combination, on human HR+/HER2+ breast cancer cell lines and mouse tumor xenograftsPLoS One2017121e016896028045951
   PubMed Web of Science ®Google Scholar
• MassarwehSThamYLHuangJA phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancerBreast Cancer Res Treat2011129381982721792626
   PubMed Web of Science ®Google Scholar
• CarlsonRWO’NeillAVidaurreTGomezHLBadveSSSledgeGWA randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancerBreast Cancer Res Treat201213331049105622418699
   PubMed Web of Science ®Google Scholar
• BursteinHJCirrincioneCTBarryWTEndocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance)J Clin Oncol201432353959396625348000
   PubMed Web of Science ®Google Scholar
• RobertsonJFFerreroJMBourgeoisHGanitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trialLancet Oncol201314322823523414585
   PubMed Web of Science ®Google Scholar
• FrogneTBenjaminsenRVSonne-HansenKActivation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrantBreast Cancer Res Treat200911422637518409071
   PubMed Web of Science ®Google Scholar
• ZamanKWinterhalderRMamotCFulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomized placebo-controlled double-blind phase II trial, SAKK 21/08Eur J Cancer201551101212122025892646
   PubMed Web of Science ®Google Scholar
• ZmajkovicovaKJesenbergerVCatalanottiFBaumgartnerCReyesGBaccariniMMEK1 is required for PTEN membrane recruitment, Akt regulation, and the maintenance of peripheral toleranceMol Cell2013501435523453810
   PubMed Web of Science ®Google Scholar
• BoschALiZBergamaschiAPI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancerSci Transl Med20157283283ra51
   PubMed Web of Science ®Google Scholar
• MillerTWBalkoJMFoxEMERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancerCancer Discov20111433835122049316
   PubMed Web of Science ®Google Scholar
• MaCXLuoJNaughtonMA phase I trial of BKM120 (bupar-lisib) in combination with fulvestrant in postmenopausal women with estrogen receptor-positive metastatic breast cancerClin Cancer Res20162271583159126563128
   PubMed Web of Science ®Google Scholar
• BaselgaJImSAIwataHBuparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trialLancet Oncol201718790491628576675
   PubMed Web of Science ®Google Scholar
• Di LeoAJohnstonSLeeKSBuparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trialLancet Oncol20181918710029223745
   PubMed Web of Science ®Google Scholar
• SunSYRosenbergLMWangXActivation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibitionCancer Res200565167052705816103051
   PubMed Web of Science ®Google Scholar
• KropIEMayerIAGanjuVPictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trialLancet Oncol201617681182127155741
   PubMed Web of Science ®Google Scholar
• JuricDRodonJTaberneroJPhosphatidylinositol 3-kinase α-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human studyJ Clin Oncol201836131291129929401002
   PubMed Web of Science ®Google Scholar
• JuricDKropIRamanathanRKPhase I dose-escalation study of taselisib, an oral PI3K Inhibitor, in patients with advanced solid tumorsCancer Discov20177770471528331003
   PubMed Web of Science ®Google Scholar
• BaselgaJDentSFCortésJPhase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPERJ Clin Oncol201836
   Web of Science ®Google Scholar
• MaCXSanchezCGaoFA phase I study of the Akt inhibitor MK-2206 in combination with hormonal therapy in postmenopausal women with estrogen receptor-positive metastatic breast cancerClin Cancer Res201622112650265826783290
   PubMed Web of Science ®Google Scholar
• KornblumNZhaoFManolaJRandomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102J Clin Oncol201836161556156329664714
   PubMed Web of Science ®Google Scholar
• FinnRSDeringJConklinDPD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitroBreast Cancer Res2009115R7719874578
   PubMed Web of Science ®Google Scholar
• TurnerNCRoJAndréFPalbociclib in hormone-receptor-positive advanced breast cancerN Engl J Med2015373320921926030518
   PubMed Web of Science ®Google Scholar
• CristofanilliMTurnerNCBondarenkoIFulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trialLancet Oncol201617442543926947331
   PubMed Web of Science ®Google Scholar
• LoiblSTurnerNCRoJPalbociclib combined with fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 resultsOncologist20172291028103828652278
   PubMed Web of Science ®Google Scholar
• TurnerNCFinnRSMartinMClinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastasesAnn Oncol201829366968029342248
   PubMed Web of Science ®Google Scholar
• VermaSBartlettCHSchnellPPalbociclib in combination with fulvestrant in women with hormone receptor-positive/HER2-negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, placebo-controlled, phase III study (PALOMA-3)Oncologist201621101165117527368881
   PubMed Web of Science ®Google Scholar
• HarbeckNIyerSTurnerNQuality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trialAnn Oncol20162761047105427029704
   PubMed Web of Science ®Google Scholar
• GianniLBisagniGColleoniMNeoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 studyLancet Oncol201819224925629326029
   PubMed Web of Science ®Google Scholar
• SledgeGWJrToiMNevenPMONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapyJ Clin Oncol201735252875288428580882
   PubMed Web of Science ®Google Scholar
• SlamonDJNevenPChiaSPhase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3J Clin Oncol Epub201863
   PubMed Web of Science ®Google Scholar
• Herrera-AbreuMTPalafoxMAsgharUEarly adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancerCancer Res20167682301231327020857
   PubMed Web of Science ®Google Scholar
• O’BrienNADi TomasoEAyalaRIn vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancerCancer Res20147419 Suppl4756
   Web of Science ®Google Scholar
• TolaneySMForero-TorresABoniVRibociclib + fulvestrant in postmenopausal women with HR+, HER2− advanced breast cancer (ABC)Cancer Res2017774 SupplP4-22-12
   Google Scholar
• ForeroAHanHSDeesECPhase IB study to assess the safety, tolerability, and clinical activity of gedatolisib in combination with palbociclib and either letrozole or fulvestrant in women with metastatic or locally advanced/recurrent breast cancer (B2151009)Poster presented at: 2017 San Antonio Breast Cancer SymposiumDecember 6–10, 2017San Antonio, TX
   Google Scholar
• MartínMLoiblSvon MinckwitzGPhase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) studyJ Clin Oncol20153391045105225691671
   PubMed Web of Science ®Google Scholar
• ClemonsMJCochraneBPondGRRandomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY studyBreast Cancer Res Treat2014146115316224924416
   PubMed Web of Science ®Google Scholar
• MusolinoACamponeMNevenPPhase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2– breast cancer that had progressed during or after prior endocrine therapyBreast Cancer Res20171911828183331
   PubMedGoogle Scholar
• AdelsonKRamaswamyBSparanoJARandomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trialNPJ Breast Cancer201621603728721390
   PubMedGoogle Scholar
• DolfiSCJägerAVMedinaDJHafftyBGYangJMHirshfieldKMFulvestrant treatment alters MDM2 protein turnover and sensitivity of human breast carcinoma cells to chemotherapeutic drugsCancer Lett20143501–2526024747123
   PubMed Web of Science ®Google Scholar
• JiangDHuangYHanNFulvestrant, a selective estrogen receptor down-regulator, sensitizes estrogen receptor negative breast tumors to chemotherapyCancer Lett2014346229229924462822
   PubMed Web of Science ®Google Scholar
• SchwartzbergLSWangGSomerBGPhase II trial of fulves-trant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancerClin Breast Cancer2014141131924268206
   PubMed Web of Science ®Google Scholar
• RobertsonJFCheungKLNoguchiSHealth-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancerEur J Cancer20189420621529574365
   PubMed Web of Science ®Google Scholar